NCT07239466 is a Phase 2 clinical trial of Short-course radiotherapy in Rectal Cancer, sponsored by Tao Zhang.

Who is sponsoring NCT07239466?

NCT07239466 is sponsored by Tao Zhang.

What drugs are being tested in NCT07239466?

Interventions in NCT07239466: Short-course radiotherapy, Capecitabine, Oxaliplatin, TME surgery, β-hydroxybutyrate.

What condition does NCT07239466 study?

NCT07239466 studies Rectal Cancer, Radiotherapy, Immunotherapy, Chemotherapy.

Is NCT07239466 still recruiting?

NCT07239466 is currently not yet recruiting. Last updated 20 November 2025.

Last reviewed 2025-11-20 · How we verify

NCT07239466

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Pilot Study Evaluating β-hydroxybutyrate Supplementation Concomitant to Short-Course Radiotherapy Followed by Immunotherapy Combined With CAPEOX Neoadjuvant Therapy in Patients With Locally Advanced Rectal Cancer

Not yet recruiting Phase 2 Last updated 20 November 2025

What this trial tests

Phase 2 trial testing Short-course radiotherapy in Rectal Cancer in 48 participants. Not yet recruiting.

Timeline

1 January 2026

Primary endpoint
31 December 2026

1 June 2027

Quick facts

Lead sponsor	Tao Zhang
Phase	Phase 2
Status	Not yet recruiting
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	48
Start date	1 January 2026
Primary completion	31 December 2026
Estimated completion	1 June 2027
Sites	1 location across China

Drugs / interventions tested

Short-course radiotherapy
Capecitabine (capecitabine) — full drug profile →
Oxaliplatin (Oxaliplatin) — full drug profile →
TME surgery
β-hydroxybutyrate

Conditions studied

Rectal Cancer — all drugs for Rectal Cancer →
Radiotherapy — all drugs for Radiotherapy →
Immunotherapy — all drugs for Immunotherapy →
Chemotherapy — all drugs for Chemotherapy →

Sponsor

Tao Zhang — full company profile →

Who can join

Adults 18 to 75, any sex, with Rectal Cancer or Radiotherapy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is a prospective phase II clinical trial aimed at exploring the potential benefits of supplementing β-hydroxybutyrate with existing short course radiotherapy sequential immunotherapy and CAPEOX therapy.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Short-course radiotherapy

Trials testing the same drug.

NCT07113275 — A Clinical Trial Comparing Long-Course Versus Short-Course Radiotherapy Followed by Immunotherapy Combined With Total Ne · Phase 3 · not yet recruiting
NCT07347951 — A Single-center, Phase II Study on Efficacy & Safety of SCRT+CAPOX+Serplulimab+Bevacizumab for MSS Rectal Cancer · Phase 2 · recruiting
NCT07150949 — Long-course Chemoradiotherapy or Short-course Radiotherapy Combined With CAPOX, PD-1antibody, and COX-2 Inhibitor for MS · Phase 2 · recruiting
NCT07040098 — Optimizing Immunotherapy Combined With Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer · Phase 2 · recruiting
NCT06872606 — Short-Course Radiotherapy Combined with Intracavitary Brachytherapy Followed by Pucotenlimab, Bevacizumab, Oxaliplatin, · Phase 2 · not yet recruiting

Other recruiting trials for Rectal Cancer

Currently open trials in the same condition.

NCT07528209 — Neoadjuvant CAPOX With or Without Pucotenlimab Plus Selective Radiotherapy for Locally Advanced Rectal Cancer · Phase 3 · recruiting
NCT07537998 — Antegrade Intestinal Fluid Reinfusion for Prevention of Low Anterior Resection Syndrome After Low Anterior Resection: a · Phase 2, PHASE3 · recruiting
NCT07501845 — Registry Maastro Applicator · recruiting
NCT07369531 — The Impact of Two-Stage Turnbull-Cutait Pull-Through Coloanal Anastomosis on Stoma-free Survival in Low Rectal Anal-pres · NA · recruiting
NCT07505472 — Efficacy and Safety Comparison of Short-course Radiotherapy Followed by CapeOX Chemotherapy Plus Toripalimab With or Wit · Phase 2, PHASE3 · recruiting

Other Tao Zhang trials

Trials by the same sponsor.

NCT07113275 — A Clinical Trial Comparing Long-Course Versus Short-Course Radiotherapy Followed by Immunotherapy Combined With Total Ne · Phase 3 · not yet recruiting
NCT07353268 — Phase Ib/II Study of QL1706 + Fruquintinib + SCRT vs. Standard Third-Line Therapy in Unresectable Liver-Metastatic pMMR/ · Phase 2 · not yet recruiting
NCT07243938 — Phase II Basket Trial: Zanidatamab Plus Tislelizumab in HER2-Positive GI Tumors (UNION-HER2-BASKET) · Phase 2 · not yet recruiting
NCT07000305 — A Study of Cetuximabβ Combined With Envolimab and mFOLFOX6 in Subjects With Advanced Colorectal Cancer · Phase 2 · not yet recruiting
NCT06484556 — T Cell Receptor Gene-Engineered T Cell Therapy Targeting KRAS Mutations in the Treatment of Subjects With Advanced Solid · Phase 1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07239466 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Tao Zhang
Last refreshed: 20 November 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07239466.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing